AR031443A1 - Metodo de determinacion de la expresion genetica de receptor de factor de crecimiento epidermico y her2-neu y correlacion de los niveles de los mismos con los indices de supervivencia - Google Patents

Metodo de determinacion de la expresion genetica de receptor de factor de crecimiento epidermico y her2-neu y correlacion de los niveles de los mismos con los indices de supervivencia

Info

Publication number
AR031443A1
AR031443A1 ARP010105562A ARP010105562A AR031443A1 AR 031443 A1 AR031443 A1 AR 031443A1 AR P010105562 A ARP010105562 A AR P010105562A AR P010105562 A ARP010105562 A AR P010105562A AR 031443 A1 AR031443 A1 AR 031443A1
Authority
AR
Argentina
Prior art keywords
neu
her2
levels
egfr
correlation
Prior art date
Application number
ARP010105562A
Other languages
English (en)
Original Assignee
Response Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/877,177 external-priority patent/US6582919B2/en
Application filed by Response Genetics Inc filed Critical Response Genetics Inc
Publication of AR031443A1 publication Critical patent/AR031443A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se relaciona con métodos de pronostico que son utiles en medicina, en particular la quimioterapia de cáncer. El objetivo de la invencion es proporcionar un método para la evaluacion de los niveles de expresion de Her2-neu y/ o EGFR en tejidos fijados o fijados y empotrados en parafina, y pronosticar la probable sensibilidad del tumor de un paciente al tratamiento con quimioterapia apuntada a quinasa de tirosina de receptor, por examen de la cantidad de ARNm de HER2-neu y/ o EGFR en las células tumorales de un paciente, y comparándola con un nivel de expresion de umbral predeterminado para esos genes. Más específicamente, la invencion proporciona pares de cebadores de oligonucleocis EGFR y HER2-neu y métodos que comprenden su uso para la deteccion de los niveles de ARNm de EGFR y de HER2-neu, respectivamente.
ARP010105562A 2000-12-01 2001-11-29 Metodo de determinacion de la expresion genetica de receptor de factor de crecimiento epidermico y her2-neu y correlacion de los niveles de los mismos con los indices de supervivencia AR031443A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25012200P 2000-12-01 2000-12-01
US25046900P 2000-12-04 2000-12-04
US09/877,177 US6582919B2 (en) 2001-06-11 2001-06-11 Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates

Publications (1)

Publication Number Publication Date
AR031443A1 true AR031443A1 (es) 2003-09-24

Family

ID=27400287

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010105562A AR031443A1 (es) 2000-12-01 2001-11-29 Metodo de determinacion de la expresion genetica de receptor de factor de crecimiento epidermico y her2-neu y correlacion de los niveles de los mismos con los indices de supervivencia
ARP090101940A AR071957A2 (es) 2000-12-01 2009-05-29 Metodo in vitro para la determinacion de un regimen de quimioterapia

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090101940A AR071957A2 (es) 2000-12-01 2009-05-29 Metodo in vitro para la determinacion de un regimen de quimioterapia

Country Status (14)

Country Link
US (1) US20030211530A1 (es)
EP (1) EP1379686B1 (es)
JP (3) JP2004536561A (es)
KR (3) KR101014342B1 (es)
CN (2) CN1488002A (es)
AR (2) AR031443A1 (es)
AU (2) AU2002232409B2 (es)
CA (1) CA2436910C (es)
ES (1) ES2394630T3 (es)
IL (2) IL156233A0 (es)
MX (2) MX2008005896A (es)
NZ (2) NZ546252A (es)
TW (3) TWI321156B (es)
WO (1) WO2002044413A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US20020064785A1 (en) 2000-05-19 2002-05-30 Genentech Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US7005278B2 (en) * 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
EP1570080A4 (en) 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
US20040258685A1 (en) * 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
RS53128B (en) 2005-02-23 2014-06-30 Genentech Inc. Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2318552B1 (en) 2008-09-05 2016-11-23 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX346956B (es) 2010-09-24 2017-04-06 Univ Leland Stanford Junior Captura directa, amplificación y secuenciación de objetivo adn usando cebadores inmovilizados.
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
TW201400810A (zh) * 2012-06-01 2014-01-01 Taiho Pharmaceutical Co Ltd 對胃癌患者選擇化學療法之方法
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
EP3001580B1 (en) * 2013-06-26 2019-01-02 Huawei Technologies Co., Ltd. Connection establishment method, device and system
GB2524948A (en) * 2014-03-07 2015-10-14 Oxford Gene Technology Operations Ltd Detecting Increase or Decrease in the Amount of a Nucleic Acid having a Sequence of Interest
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
CN105713963A (zh) * 2014-12-05 2016-06-29 上海药明康德新药开发有限公司 从福尔马林固定石蜡包埋的组织样品中检测基因表达的方法
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN108342464A (zh) * 2018-04-04 2018-07-31 良培基因生物科技（武汉）有限公司 一步法检测HER2/neu基因表达量的试剂盒及其检测方法
CN112430646A (zh) * 2020-12-11 2021-03-02 南京求臻基因科技有限公司 一种基于数字pcr平台的egfr基因扩增的检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4830969A (en) * 1981-08-31 1989-05-16 The Research Foundation Of State University Of New York Process for the rapid and simple isolation of nucleic acids
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5620852A (en) * 1990-11-14 1997-04-15 Hri Research, Inc. Nucleic acid preparation methods
US5654179A (en) * 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
US5284940A (en) * 1990-11-14 1994-02-08 Hri Research, Inc. Preparation for nucleic acid samples
US5346994A (en) * 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
US5502166A (en) * 1992-02-26 1996-03-26 Mitsubishi Chemical Corporation NMDH receptor proteins and genes encoding the same
US5693474A (en) * 1992-05-13 1997-12-02 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5639613A (en) * 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
AU6230594A (en) * 1993-02-01 1994-08-29 University Of Iowa Research Foundation, The Quartenary amine surfactants and methods of using same in isolation of rna
US5637687A (en) * 1993-08-31 1997-06-10 Wiggins; James C. Methods and compositions for isolating nucleic acids
ATE234919T1 (de) * 1993-12-23 2003-04-15 Biognostik Ges Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5643767A (en) * 1994-05-02 1997-07-01 The Rockefeller University Process for isolating cellular components
CA2153215A1 (en) * 1994-07-06 1996-01-07 Lu Wang Treatment of paraffin embedded tissue for gene analysis
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5707802A (en) * 1995-01-13 1998-01-13 Ciba Corning Diagnostics Corp. Nucleic acid probes for the detection and identification of fungi
US5777099A (en) * 1995-02-24 1998-07-07 Biotecx Laboratories, Inc. RNA separation
US5945515A (en) * 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
DE29601618U1 (de) * 1996-01-31 1996-07-04 InViTek GmbH, 13125 Berlin Vorrichtung zur gleichzeitigen multiplen Isolierung
EP0791654A1 (en) * 1996-02-21 1997-08-27 Jürgen A. Dr. Richt Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
EP0912726A4 (en) * 1996-05-10 2001-07-18 Phylomed Corp METHODS FOR OXIDIZING BISULFIDE LINKS WITH OZONE
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
CA2301924C (en) * 1997-08-20 2008-12-09 The University Of Miami A high quality, continuous throughput, tissue fixation-dehydration-fat removal-impregnation method
US6183995B1 (en) * 1997-09-05 2001-02-06 Lifespan Biosciences, Inc. Methods of measuring gene expression using wax-embedded tissue specimens
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
US6204375B1 (en) * 1998-07-31 2001-03-20 Ambion, Inc. Methods and reagents for preserving RNA in cell and tissue samples
US6180349B1 (en) * 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6444465B1 (en) * 2000-09-29 2002-09-03 Isis Pharmaceuticals, Inc. Antinsense modulation of Her-1 expression
TWI319010B (en) * 2000-12-01 2010-01-01 Response Genetics Inc Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors

Also Published As

Publication number Publication date
KR20090100465A (ko) 2009-09-23
TWI321156B (en) 2010-03-01
NZ546252A (en) 2008-03-28
IL156233A0 (en) 2004-01-04
AU2002232409B2 (en) 2006-12-07
CN1488002A (zh) 2004-04-07
JP2004536561A (ja) 2004-12-09
TWI312809B (en) 2009-08-01
KR100946980B1 (ko) 2010-03-17
EP1379686A2 (en) 2004-01-14
ES2394630T3 (es) 2013-02-04
KR20030074640A (ko) 2003-09-19
NZ546251A (en) 2008-01-31
EP1379686B1 (en) 2012-09-05
KR101014342B1 (ko) 2011-02-15
WO2002044413A3 (en) 2003-11-06
US20030211530A1 (en) 2003-11-13
CA2436910C (en) 2014-06-17
TWI313711B (en) 2009-08-21
CA2436910A1 (en) 2002-06-06
JP4510915B2 (ja) 2010-07-28
AR071957A2 (es) 2010-07-28
TW200833847A (en) 2008-08-16
MXPA03004929A (es) 2005-09-08
TW200833846A (en) 2008-08-16
MX2008005896A (es) 2009-03-03
WO2002044413A2 (en) 2002-06-06
CN102220414A (zh) 2011-10-19
IL156233A (en) 2010-04-29
JP2009131267A (ja) 2009-06-18
JP2010162033A (ja) 2010-07-29
AU3240902A (en) 2002-06-11
KR20100101709A (ko) 2010-09-17

Similar Documents

Publication Publication Date Title
AR031443A1 (es) Metodo de determinacion de la expresion genetica de receptor de factor de crecimiento epidermico y her2-neu y correlacion de los niveles de los mismos con los indices de supervivencia
AR031455A1 (es) Metodo para determinar un regimen quimioterapeutico basado en la expresion de ercc1
AR032917A1 (es) Metodo para determinar la expresion de genes de dihidropirimidina deshidrogenasa
Rose et al. Osteoactivin promotes breast cancer metastasis to bone
Bouchalova et al. Triple negative breast cancer-BCL2 in prognosis and prediction. Review
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
ES2851925T3 (es) Inhibidores de MET e IGSF1 para el tratamiento de cáncer
Mese et al. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma
Chen et al. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer
NO20092339L (no) Universal tumorcellevaksine for anti-cancer terapeutisk og profylaktisk anvendelse
Liu et al. Hsa_circ_0000337 promotes proliferation, migration and invasion in glioma by competitively binding miRNA-942-5p and thus upregulates MAT2A.
Sasmana et al. Clinicopathological and prognostic significance of SRY-box transcription factor 2 (SOX2) overexpression in central nervous system tumor: a meta-analysis
KR102150239B1 (ko) Ｄｒｇ２ 억제제를 유효성분으로 포함하는 항암용 조성물
Li et al. CCNG2 suppressor biological effects on thyroid cancer cell through promotion of CDK2 degradation
Luxen et al. MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility
Zhao et al. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression
Byrne et al. The immunohistochemical detection of cripto‐1 in benign and malignant human bladder
Ni et al. Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptasepolymerase chain reaction
Symeonidis et al. Correlation between LGR5 stem cells and location of tumor as well as age, sex and metastasis in colon adenocarcinoma
Fu et al. The Dysregulation Expression of Cyclin G2 in NSCLC and Its Significance.
Savabkar et al. VEGF gene+ 936C/T polymorphism decreases the risk of colorectal cancer
Sexton et al. DEVELOPMENT AND VALIDATION OF CYSTECTOMY ASSESSMENT AND SURGICAL EVALUATION (CASE) SCORING FOR MALE RADICAL CYSTECTOMY: MP34-10
Zhou et al. TSPAN13 is overexpressed in ER-positive breast cancers and contributes to tumor progression
Silvers et al. MP17-02 TENASCIN C EXPRESSION IN BENIGN PELVIC LYMPH NODES CORRELATES WITH METASTATIC STATUS AND SURVIVAL

Legal Events

Date Code Title Description
FC Refusal